Showing 4551-4560 of 5771 results for "".
- AMA Issues CPT Category III Codes for Artificial Iris Implantationhttps://modernod.com/news/ama-issues-cpt-category-iii-codes-for-artificial-iris-implantation/2478255/VEO Ophthalmics announced that the American Medical Association (AMA) has issued three CPT codes for the “Insertion of Iris Prosthesis.” The CPT Category III codes are: 0616T, 0617T, and 0618T and are effective July 1, 2020. Earlier this year, the
- BVI Expands Malosa Single-Use Instrument Range in the UShttps://modernod.com/news/bvi-expands-malosa-single-use-instrument-range-in-the-us/2478253/BVI announced the extension of its Malosa range of single-use ophthalmic instruments in the US. The US Malosa portfolio will now include specialty instruments for use in corneal refractive surgery, complementing the existing single-use product range for cataract, oculoplastic, and office-based pr
- Graybug Vision Appoints Robert Breuil as Chief Financial Officerhttps://modernod.com/news/graybug-vision-appoints-robert-breuil-as-chief-financial-officer/2478245/Graybug Vision announced the appointment of Robert S. Breuil as chief financial officer, effective immediately. Mr. Breuil succeeds Daniel Geffken, founder and managing director of Danforth Advisors, who led the function as ad-interim CFO. “I am excited to welcome Robert Breuil to the Gray
- Quantel Medical Launches Mosar High-Definition Imaging System for for Easyrethttps://modernod.com/news/quantel-medical-lauches-mosar-high-definition-imaging-system-for-for-easyret/2478247/Quantel Medical announced the launch of Mosar, a high-definition imaging system, on its yellow laser Easyret. Mosar features an HD camera, a screen and computer, and enhances the retinal laser treatment procedu
- EnChroma Lens Technology Addresses Low Vision and Age-Related Eye Conditionshttps://modernod.com/news/enchroma-lens-technology-addresses-low-vision-and-age-related-eye-conditions/2478241/EnChroma announced the EnChroma Lx Lens Technology, a new lens series and eyewear designed for low vision and people 50+ with glare sensitivity, to address a rapidly growing category of visual challenges worldwide. EnChroma Lx Technology is specially engineered to sup
- LumiThera Receives $1.5 Million Grant From National Eye Institute to Support Trial for Treating Diabetic Retinopathy and Macular Edemahttps://modernod.com/news/lumithera-receives-1-5-million-grant-from-national-eye-institute-to-support-trial-for-treating-diabetic-retinopathy-and-macular-edema/2478242/LumiThera announced it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI). The grant supports a prospective, randomized, multicenter human clinical trial in U.S. subjects diag
- Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020https://modernod.com/news/genentech-to-present-new-data-in-multiple-sclerosis-and-neuromyelitis-optica-spectrum-disorder-at-msvirtual2020/2478238/Genentech announced that new multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) data will be presented at MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) – European Committee for Treatment and Research in Mul
- Sanofi, GSK Start Phase 1/2 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/sanofi-gsk-start-phase-1-2-study-of-covid-19-vaccine-candidate/2478239/Sanofi and GlaxoSmithKline announced Thursday the start of a phase 1/2 study of their experimental adjuvanted COVID-19 vaccine, with plans to move to late-stage trials this year. The companies added that in parallel, they are scaling up manufacturing of the antigen and adjuvant with the target of
- Nicox Completes Enrollment of the Adaptive Design Cohort of NCX 470 Mont Blanc Phase 3 Glaucoma Trialhttps://modernod.com/news/nicox-completes-enrollment-of-the-adaptive-design-cohort-of-ncx-470-mont-blanc-phase-3-glaucoma-trial/2478234/Nicox SA announced that it completed enrollment of the adaptive design patient cohort in its multicenter Mont Blanc phase 3 trial, evaluating NCX 470 ophthalmic solution vs. latanoprost ophthalmic solution 0.005% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.
- Injectsense Receives Breakthrough Device Program Designation From FDA for IOP Monitoring Systemhttps://modernod.com/news/injectsense-receives-breakthrough-device-program-designation-from-fda-for-iop-monitoring-system/2478233/Injectsense announced it has received a breakthrough device program (BDP) designation from the FDA for its chronic continuous IOP monitoring system for glaucoma patients. The company’s IOP Connect system is based on a long-term implantable sensor, smaller than a grain of rice, that is delivered t